SCHEMBL4830065

SCHEMBL4830065

O=C(C1CCCCC1)N1CCc2ccccc2C1CCN1CCC(c2cccc3c2OCC3)CC1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.51
ALDH1A1 P00352 1/20 0.51
MTNR1B P49286 3/20 0.45
DRD2 P14416 7/20 0.42
HTR2A P28223 7/20 0.42
DRD3 P35462 7/20 0.42
KEAP1 Q14145 4/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
NFE2L2 Q16236 2/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTR1A P08908 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4836909 0.99 NPSR1 (0.49) NPSR1ALDH1A1MTNR1BDRD2HTR2A
SCHEMBL4837162 0.86 DRD2 (0.40) DRD2HTR2ADRD3HTR1DHTR1B
SCHEMBL4835975 0.84 NPSR1 (0.57) NPSR1ALDH1A1MTNR1BKEAP1NFE2L2
SCHEMBL4839787 0.83 HTR2A (0.47) DRD2HTR2ADRD3
SCHEMBL4833495 0.83 ALDH1A1 (0.55) NPSR1ALDH1A1MTNR1BKEAP1NFE2L2
SCHEMBL4839490 0.82 HTR2A (0.47) DRD2HTR2ADRD3HTR1DHTR1B
SCHEMBL4838819 0.81 NPSR1 (0.53) NPSR1ALDH1A1MTNR1BDRD2KEAP1
SCHEMBL4836850 0.81 NPSR1 (0.53) NPSR1ALDH1A1MTNR1BDRD2KEAP1
SCHEMBL4839157 0.80 ALDH1A1 (0.52) NPSR1ALDH1A1MTNR1BDRD2KEAP1
SCHEMBL4829995 0.80 NPSR1 (0.50) NPSR1ALDH1A1MTNR1BDRD2KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP claimed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 NPSR1 167/4885ALDH1A1 639/4885MTNR1B 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.